Hikma Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Hikma Pharmaceuticals has a total shareholder equity of $2.3B and total debt of $1.2B, which brings its debt-to-equity ratio to 53.2%. Its total assets and total liabilities are $4.8B and $2.5B respectively. Hikma Pharmaceuticals's EBIT is $712.0M making its interest coverage ratio 11. It has cash and short-term investments of $260.0M.
Key information
53.2%
Debt to equity ratio
US$1.22b
Debt
| Interest coverage ratio | 11x |
| Cash | US$260.00m |
| Equity | US$2.30b |
| Total liabilities | US$2.55b |
| Total assets | US$4.85b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: HIKL's short term assets ($2.3B) exceed its short term liabilities ($1.4B).
Long Term Liabilities: HIKL's short term assets ($2.3B) exceed its long term liabilities ($1.2B).
Debt to Equity History and Analysis
Debt Level: HIKL's net debt to equity ratio (41.9%) is considered high.
Reducing Debt: HIKL's debt to equity ratio has increased from 34.1% to 53.2% over the past 5 years.
Debt Coverage: HIKL's debt is well covered by operating cash flow (47.8%).
Interest Coverage: HIKL's interest payments on its debt are well covered by EBIT (11x coverage).